[A case responding to weekly paclitaxel therapy as second-line chemotherapy for gastric cancer previously treated with TS-1].
A 58-year-old male patient with the recurrence of para-aortic lymphnodes after TS-1 treatment was treated by a weekly infusion of paclitaxel as second-line chemotherapy. Paclitaxel was administered at a weekly dose of 70 mg/m2/day for three weeks followed by a one week interval. After 2 courses, the tumor was reduced, and the reduction was judged as PR. Moreover, after 5 courses, the tumor was more remarkably reduced and the reduction was judged as CR. The grade 2 leukopenia, neutropenia, and grade 1 alopecia were observed as adverse events. Recently, we treated 11 patients of advanced or recurrent gastric cancers with measurable lesions, using the weekly paclitaxel therapy after TS-1 treatment. The response rate was 36.4%. The median duration of PR was 130 days. Therefore, a weekly paclitaxel regimen was considered to be one of the promising regimens for advanced or recurrent gastric cancer as the second-line chemotherapy after TS-1 treatment.
Imamura
Hiroshi
H
Dept. of Surgery, Sakai City Hospital.
Furukawa
Hiroshi
H
Kishi
Kentaro
K
Tatsuta
Masayuki
M
Masutani
Seizo
S
Fukunaga
Mutsumi
M
Nakayama
Takahiro
T
Shimizu
Junzo
J
Takemoto
Hiroyoshi
H
Kishimoto
Tomono
T
Kato
Hitoshi
H
Yamamoto
Kazuyoshi
K
Fujishima
Makoto
M
Kawasaki
Takatoshi
T
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D017239:Paclitaxel / Q000008:administration & dosage*; D011725:Pyridines / Q000627:therapeutic use*; D005641:Tegafur / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel